Telix Pharmaceuticals Limited (ASX:TLX)
Australia
· Delayed Price · Currency is AUD 28.04
-1.12 (-3.84%)
May 6, 2025, 4:10 PM AEST
Telix Pharmaceuticals Revenue
In the year 2024, Telix Pharmaceuticals had annual revenue of 783.21M AUD with 55.85% growth. Telix Pharmaceuticals had revenue of 209.62M in the quarter ending December 31, 2024, with 48.82% growth.
Revenue
783.21M
Revenue Growth
+55.85%
P/S Ratio
12.10
Revenue / Employee
1.85M
Employees
234
Market Cap
9.47B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 783.21M | 280.66M | 55.85% |
| Dec 31, 2023 | 502.55M | 342.45M | 213.90% |
| Dec 31, 2022 | 160.10M | 152.50M | 2,007.64% |
| Dec 31, 2021 | 7.60M | 2.38M | 45.71% |
| Dec 31, 2020 | 5.21M | 1.73M | 49.58% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| CSL Limited | 24.61B |
| Pro Medicus | 184.58M |
| Cochlear | 2.31B |
| Sonic Healthcare | 9.33B |
| Ramsay Health Care | 17.12B |
| Ansell | 3.00B |
| Mesoblast | 9.16M |
| Regis Healthcare | 1.10B |
Telix Pharmaceuticals News
- 11 hours ago - ATTENTION Telix Pharmaceuticals Limited Investors: You May Have Been Affected by Fraud- Contact Levi & Korsinsky to Discuss Your Rights - Accesswire
- 1 day ago - Telix Pharmaceuticals Limited INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by Telix Pharmaceuticals Limited (TLX) - Accesswire
- 4 days ago - Telix Pharmaceuticals Limited INVESTIGATION: Levi & Korsinsky Investigates Potential Securities Fraud by Telix Pharmaceuticals Limited (TLX) - Accesswire
- 5 days ago - TLX STOCK ALERT: Levi & Korsinsky Notifies Telix Pharmaceuticals Limited Investors of an Ongoing Investigation - Accesswire
- 6 days ago - TLX ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Telix Pharmaceuticals Limited - Accesswire
- 8 days ago - Telix's Illuccix PSMA-PET Imaging Agent Approved in France - GlobeNewsWire
- 8 days ago - Levi & Korsinsky Announces an Investigation on Behalf of Telix Pharmaceuticals Limited (TLX) Shareholders Who May Have Been Affected by Fraud - Accesswire
- 14 days ago - Telix Pharmaceuticals reports Q1 results; reaffirms FY25 outlook - Seeking Alpha